Rosiglitazone has been shown to inhibit VEGF-induced angiogenesis [141] and is suggested as a treatment option for vascular disorders associated with diabetes such as diabetic retinopathy, macular degeneration, and so forth. Here, VEGFA is linked to diabetes mellitus.